Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intranasal insulin is a delivery method that administers insulin through the nasal cavity, allowing it to reach the central nervous system while minimizing systemic absorption and peripheral side effects. It rapidly accumulates in cerebrospinal fluid, indicating efficient transport to the brain. This administration route enables insulin to exert functional effects on metabolism (reducing food intake and body weight, improving glucose homeostasis) and cognition (enhancing memory performance in both healthy individuals and patients with mild cognitive impairment or Alzheimer's disease). Intranasal insulin also modulates neuroendocrine activity, sleep-related mechanisms, sensory perception, and mood. It is being investigated as a potential treatment for cognitive disorders, particularly Alzheimer's disease, based on the concept that impairments in central nervous insulin signaling may be a pathophysiological factor in metabolic and cognitive disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on intranasal insulin.